[A22-33] Vedolizumab (antibiotic refractory chronic pouchitis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2022
Project no.:
A22-33
Commission:
Commission awarded on 28.03.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults with moderately to severely active chronic pouchitis, who have had an inadequate response with or lost response to antibiotic therapy or have had intolerance to this treatment, and who had undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-23 | Vedolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |